Potential predictive value of JAK2 expression for Pan-cancer response to PD-1 blockade immunotherapy

Immunotherapy represents a recent major breakthrough in cancer treatment. In particular, programmed cell death protein-1 (PD-1), programmed cell death ligand 1 (PD-L1), and PD-L2 pathways constitute key immune checkpoints. The PD-1 inhibitors nivolumab and pembrolizumab have induced durable control and shown a survival benefit in immunogenic tumors, such as non-small cell lung carcinoma, melanoma, renal cell carcinoma, and head and neck cancer (1)